ABCAM PLC First Half Trading Update
CAMBRIDGE, England, July 20, 2022 /PRNewswire/ -- Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release it...
Abcam: Appointment of Vice President of Investor Relations
CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam
Abcam the most awarded company at 2022 industry awards
CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar
Biosciences
Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus
Biotechnology, Inc
Abcam completes $340m strategic acquisition and expands kit capacity and capability
- Completing $340m strategic acquisition of BioVision
- Expanding facilities in Eugene, further growing kits and assays portfolio
- Supporting the growing demand of the sector and accelerating execution of
strategic plan
CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire/ -- Abcam
Abcam reveals new cell engineering facility in Bay Area
CAMBRIDGE, England, Dec. 8, 2020 /PRNewswire/ -- Today Abcam
